^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    STRN (Striatin)

    i
    Other names: STRN, Striatin, Protein Phosphatase 2 Regulatory Subunit B'''Alpha, Striatin Calmodulin Binding Protein, Striatin Calmodulin-Binding Protein, PPP2R6A, SG2NA, STRN1
    5ms
    Papillary Thyroid Carcinoma With an STRN::ALK Fusion Arising From a Mature Ovarian Teratoma. (PubMed, Int J Gynecol Pathol)
    Next-generation sequencing revealed an STRN::ALK fusion, supported by positive ALK immunohistochemistry in the carcinoma. The identification of these genetic signatures not only aids in diagnosis but also provides potential therapeutic targets in the case of disease progression.
    Journal
    |
    ALK (Anaplastic lymphoma kinase) • STRN (Striatin)
    |
    ALK positive • ALK fusion
    7ms
    Striatin (STRN): A multifunctional protein in cardiovascular health and cancer progression. (PubMed, Biomed Pharmacother)
    This review synthesizes current findings on the STRN dual role in cardio-oncology, highlighting its molecular mechanisms and potential therapeutic implications. However, additional research is required for a deeper understanding of STRN-mediated signaling, which may lead to the development of novel biomarkers for interventions in cardio-oncology.
    Review • Journal
    |
    ALK (Anaplastic lymphoma kinase) • STRN (Striatin)
    |
    ALK fusion
    7ms
    Alectinib efficacy in advanced lung adenocarcinoma with coexistence of a novel ALK-MTUS2 and STRN3-ALK double fusion: A case report and literature review. (PubMed, Oncol Lett)
    To the best of our knowledge, the present study represents the first discovery of simultaneous ALK-MTUS2 and STRN3-ALK fusions. The clinical outcome offers potential therapeutic options for patients with rare ALK rearrangements and underscores the necessity for further research on the functions of these fusions.
    Journal
    |
    ALK (Anaplastic lymphoma kinase) • STRN (Striatin)
    |
    ALK rearrangement • ALK fusion
    |
    Alecensa (alectinib)
    9ms
    Case Report: ALK-rearranged mesenchymal neoplasms with S100 and CD34 co-expression: additional cases with distinct characteristics. (PubMed, Front Oncol)
    In case 1, no indications of disease progression or metastasis was observed within the limited follow-up (36 months). However, the patient in case 2 experienced a rapid recurrence and metastasis.
    Journal
    |
    ALK (Anaplastic lymphoma kinase) • STRN (Striatin) • CD34 (CD34 molecule) • NTRK (Neurotrophic receptor tyrosine kinase) • PLEKHH2 (Pleckstrin Homology, MyTH4 And FERM Domain Containing H2)
    |
    ALK rearrangement • ALK fusion
    |
    VENTANA ALK (D5F3) CDx Assay
    10ms
    Clinicopathological and molecular characterization of KRAS wild-type pancreatic ductal adenocarcinomas reveals precursor lesions with oncogenic mutations and fusions in RAS pathway genes. (PubMed, J Pathol)
    © 2025 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland
    Journal
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • NRAS (Neuroblastoma RAS viral oncogene homolog) • FGFR2 (Fibroblast growth factor receptor 2) • FGFR3 (Fibroblast growth factor receptor 3) • EML4 (EMAP Like 4) • FGFR1 (Fibroblast growth factor receptor 1) • HRAS (Harvey rat sarcoma viral oncogene homolog) • MAP2K1 (Mitogen-activated protein kinase kinase 1) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • STRN (Striatin) • ERBB4 (erb-b2 receptor tyrosine kinase 4) • CFAP58 (Cilia And Flagella Associated Protein 58)
    |
    KRAS mutation • EGFR mutation • BRAF mutation • NRAS mutation • FGFR2 mutation • KRAS wild-type • FGFR2 fusion • ALK fusion • ALK mutation • RAS wild-type • HRAS mutation • AKT1 mutation
    11ms
    High-Grade Papillary Thyroid Carcinoma, Diffuse Sclerosing Subtype: A Series of 18 Cases Detailing the Pathologic Features, Potential for Misdiagnosis, and Aggressive Clinical Behavior. (PubMed, Am J Surg Pathol)
    In conclusion, HGPTC-DS is a rare high-grade carcinoma characterized by uniform squamoid area with comedo-type tumor necrosis, high pT stage, gross ETE, large volume nodal metastasis, poor RFS, and RRFS. Given its rarity, it may be subjected to misdiagnosis as PTC and anaplastic carcinoma.
    Journal
    |
    BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • RET (Ret Proto-Oncogene) • STRN (Striatin)
    |
    BRAF V600E • BRAF V600 • RET fusion • ALK fusion
    11ms
    Mineralocorticoid Receptor (MR) Antagonist (Eplerenone) vs Amlodipine and STRIATIN (clinicaltrials.gov)
    P4, N=90, Completed, Brigham and Women's Hospital | N=400 --> 90
    Enrollment change
    |
    STRN (Striatin)
    1year
    A rationale for the poor response to alectinib in a patient with adenocarcinoma of the lung harbouring a STRN-ALK fusion by artificial intelligence and molecular modelling: a case report. (PubMed, Transl Lung Cancer Res)
    Our model calculations suggested that the effect of the translocation was to induce the dimerization of ALK into a complex that distorted the binding pocket, which is the same for alectinib, lorlatinib and crizotinib. Our observations suggest that molecular modelling based on artificial intelligence (AI) tools may offer potential predictive information in fusions with rare partner genes. Further retrospective and prospective studies are warranted to demonstrate the predictive robustness of these tools.
    Journal
    |
    ALK (Anaplastic lymphoma kinase) • STRN (Striatin)
    |
    ALK fusion • ALK translocation
    |
    Xalkori (crizotinib) • Alecensa (alectinib) • Lorbrena (lorlatinib)
    1year
    Alectinib for the treatment of papillary thyroid carcinoma harbouring STRN - ALK fusion. (PubMed, Eur J Cancer)
    Here we report the first case in Europe of STRN - ALK translocated advanced thyroid carcinoma successfully treated with alectinib.
    Journal
    |
    ALK (Anaplastic lymphoma kinase) • STRN (Striatin)
    |
    ALK rearrangement • ALK fusion • ALK translocation
    |
    Alecensa (alectinib)
    1year
    HBV Remodels PP2A Complexes to Rewire Kinase Signaling in Hepatocellular Carcinoma. (PubMed, Cancer Res)
    mTORC2-mediated upregulation of YAP was observed in human HCC specimens and mouse HCC models and could be targeted with mTOR kinase inhibitors. Thus, HBV interaction with host proteins rewires HCC signaling rather than directly activating mitogenic pathways, provide an alternative paradigm for the cellular effects of a tumor promoting virus.
    Journal
    |
    STRN (Striatin)
    1year
    The Multifaceted Role of Striatin-interacting Protein 2 (STRIP2) in Disease Pathogenesis and Cancer Progression. (PubMed, Anticancer Res)
    It is involved in critical oncogenic pathways including proliferation, EMT, and immune regulation, highlighting its potential as a therapeutic target. This review supports the importance of investigating the diagnostic, prognostic, and therapeutic role of STRIP2 in various cancers, particularly NSCLC.
    Review • Journal
    |
    STRN (Striatin)
    over1year
    STRN-ALK Fusion in Advanced Salivary Gland Carcinoma With Response to Anaplastic Lymphoma Kinase Inhibition: Case Report and Literature Review. (PubMed, WMJ)
    Our patient experienced clinical benefit from first and second generation ALK inhibition in a chemotherapy refractory tumor. Tumor mutation profiling can identify mutations that may render tumors sensitive to targeted therapy with tyrosine kinase inhibitors.
    Review • Journal • Metastases
    |
    ALK (Anaplastic lymphoma kinase) • STRN (Striatin)
    |
    ALK fusion • ALK translocation • STRN-ALK fusion